UBS Maintains Buy on AdaptHealth, Lowers Price Target to $10

Benzinga · 3d ago
UBS analyst Kevin Caliendo maintains AdaptHealth (NASDAQ:AHCO) with a Buy and lowers the price target from $14 to $10.